---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-24-000003"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:31:36.775517+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GeneDx prelim Q4 revenue >$57M, exome/genome rev +63% YoY; cash burn -51% YoY

## Summary
- Q4 continuing ops revenue >$57M (+24% YoY); exome/genome revenue >$38M (+63% YoY).
- Exome/genome test results 15,663 in Q4 (+99% YoY), now 27% of total test volume.
- Cash and equivalents $131M as of Dec 31, 2023.
- Q4 cash burn $33M, down 51% YoY and 21% sequentially; reiterates 2025 profitability path.
- Full year 2023 continuing ops revenue expected at least $193M; exceeded revised guidance.

## SEC filing metadata
- accession: 0001818331-24-000003
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/0001818331-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/wgs-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-24-000003
- JSON: https://secwatch.observer/filing/0001818331-24-000003.json
- Plain text: https://secwatch.observer/filing/0001818331-24-000003.txt

## Key facts
- Earnings Releases
  GeneDx Holdings Corp. reported full year 2023 results: revenue at least $193 million. Guidance reaffirmed.
  - Period: full year 2023
  - Revenue: at least $193 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Management expects GeneDx to report: • revenues of at least $193 million for full year 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/0001818331-24-000003-index.htm
- Earnings Releases
  GeneDx Holdings Corp. reported fourth quarter of 2023 results: revenue at least $57 million. Guidance reaffirmed.
  - Period: fourth quarter of 2023
  - Revenue: at least $57 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Financial Results (Unaudited) Continuing Operations Results: 1 Management expects GeneDx to report: • revenues of at least $193 million for full year 2023 • revenues of at least $57 million in the fourth quarter, an increase of 24% year-over-year and 13% sequentially; • exome and genome test revenues of at least $38 million in the fourth quarter, an increase of 63%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000003/0001818331-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.